Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
Volume: 34, Issue: 15_suppl, Pages: 6096 - 6096
Published: May 20, 2016
Abstract
6096Background: Recurrent/metastatic adenoid cystic carcinoma (R/M ACC) is incurable. Regorafenib (BAY 73-4506; Bayer) is a tyrosine kinase inhibitor (TKI) that targets receptor tyrosine kinases...
Paper Details
Title
Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.
Published Date
May 20, 2016
Journal
Volume
34
Issue
15_suppl
Pages
6096 - 6096
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History